ViCentra Secures $98 Million to Expand Kaleido Patch Pump for European Market and U.S. Access

ViCentra Expands Financing to Accelerate Market Access

ViCentra, a trailblazer in medical devices within Europe, has made significant strides towards enhancing its operations and expanding its market access. On January 8, 2026, the company announced a successful second close of its Series D financing round, adding another $13 million to its already impressive total of $98 million.

This funding round has seen contributions from ROM Utrecht Region and a coalition of Dutch investors, including Venturing Tech. Moreover, it highlights the ongoing support from existing investor Innovation Industries. With this robust financial backing, ViCentra aims to not only scale up its manufacturing capabilities but also enhance its commercial ventures across Germany, the Netherlands, and France, while gearing up for entry into the U.S. market.

The past year has proven to be transformative for ViCentra. Having raised $85 million just a few months prior in September 2025, the company's momentum speaks volumes about the confidence investors have in its strategic direction, operational efficiency, and market traction. ViCentra's flagship product, the Kaleido insulin patch pump, is already distinguished in the market as the lightest and most precise delivery system available. It is designed to blend medical innovation with personal style, offering customizable aluminum shells in a palette of ten vibrant colors.

CEO Tom Arnold expressed enthusiasm about the recent developments, stating, ‘This latest funding empowers us to enhance our manufacturing capabilities and boost our presence in key markets. Our focused goal for 2026 is to convert the high demand for our product into a larger user base while ensuring uncompromised quality in insulin delivery.’ Arnold also emphasized a vision to nearly triple their European user base by the end of 2026.

Throughout 2025, the company exhibited remarkable growth, doubling its user base to over 4,000 and reflecting significant revenue increases alongside the expansion of its manufacturing capacity. The reinforcement of ViCentra's market presence in Germany, specifically, is significant as Germany stands as the world's second-largest insulin pump market, with keen interest in innovative, user-friendly medical devices.

ViCentra's leadership team is scheduled to engage with investors and strategic partners in upcoming conferences, notably the J.P. Morgan Healthcare Conference in San Francisco, followed by the LSI USA '26 Emerging Medtech Summit in Dana Point in March. Interested parties can reach out to Optimum Strategic Communications for meeting arrangements.

About ViCentra

Founded with a mission to enhance the lives of those with diabetes, ViCentra focuses on empathetic innovation and design excellence. Its Kaleido insulin patch pump is a game-changer, offering a discreet and flexible alternative to conventional insulin pumps. Based in Utrecht, the Netherlands, the company is making strides in expanding its reach across Europe while preparing for dynamic entry into the U.S. market. Investors like Innovation Industries, Partners in Equity, Invest-NL, and EQT Life Sciences support ViCentra's ambitions. For further details, visit ViCentra's website.

About Kaleido

The Kaleido insulin patch pump is reimagining how diabetes management is perceived, emphasizing a combination of functionality, adaptability, and lifestyle integration. Compact and light, it utilizes top-quality materials and comes in customizable designs to support self-expression. This innovative device not only facilitates insulin delivery but does so with the unobtrusiveness of a lifestyle gadget rather than a medical one. The integration with advanced algorithms like Diabeloop's DBLG1 and DBLG2 offers enhanced insulin therapy automation, positioning Kaleido at the forefront of the diabetes care market.